AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01375738 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en Y gastrojejunostomy
Description: After subtotal gastrectomy with lymph node dissection, the jejunum is transected 25\~30cm distal to the ligament of Treitz. Distal jejunum is drawn up and sutured to the gastric remnant and the proximal jejunum is anastomosed to the distal jejunum at 30\~40cm from the new gastric-jejunal junction.
Study NCT00106340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT00106340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT01375738 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastroduodenostomy
Description: After subtotal gastrectomy with lymph node dissection, the gastric remnant is anastomosed to duodenum 1st portion with circular or linear staplers and the artificial lesser curvature is repaired with linear stapler.
Study NCT02162654 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham preconditioning
Description: The blood pressure cuff is inflated to 10 mmHg for 3 x 5 minutes with 5 minutes of complete cuff deflation each.
Study NCT02819531 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rotational atherectomy
Description: Pre-stenting lesion modification using the rotational atherectomy device using standard technique under intravenous infusion of heparin. Burr size will be selected by the operator according to vessel size. IVUS images will be obtained before lesion modification and after stenting.
Study NCT01135745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reclaim® Deep Brain Stimulation
Description: Implant of leads in pre-defined brain area; implant of neurostimulators
Study NCT02819531 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orbital atherectomy
Description: Pre-stenting lesion modification using the orbital atherectomy device according the manufacturer's guidelines. IVUS images will be obtained before lesion modification and after stenting.
Study NCT02819531 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Scoring balloon system
Description: Pre-stenting lesion modification using the scoring balloon system according the manufacturer's guidelines. IVUS images will be obtained before lesion modification and after stenting.
Study NCT01833858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose HCG
Description: Low dose hCG (200 IU per day) will be given daily when at least six follicles of 12 mm will be observed and E2 (Estradiol) levels are higher than 600 ng/l, until the day of the HCG trigger administration.
Study NCT03268369 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PET scan [18F]FDG
Description: exam performed after iv injection of 200 MBq \[18F\]FDG
Study NCT03268369 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET scan [18F]FDG
Description: exam performed after iv injection of 200 MBq \[18F\]FDG
Study NCT03498092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-Dexmedetomidine
Description: isobaric bupivacaine 2.5 mg/ml plus 5 micro gram/ml adrenaline and 1 micro gram/kg dexmedetomidine in a volume of 0.5 ml/kg
Study NCT03498092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: isobaric bupivacaine 2.5 mg/ml plus 5 micro gram/ml adrenaline in a volume of 0.5 ml/kg
Study NCT03498092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: General anesthesia
Description: Normal saline in a volume of 0.5 ml/kg
Study NCT01833858 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients received rFSH injections with Placebo starting on cycle day 3 of the stimulation cycle until the day of hCG trigger administration.
Study NCT00295282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDX-1100 (anti-CXCL10 human monoclonal antibody)
Description: Patients will receive a single dose of MDX-1100 at 0.3, 1.0, 3.0 or 10 mg/kg as a 60 minute intravenous infusion. Patients who respond to treatment may receive up to an additional 3 doses of MDX-1100.
Study NCT01397045 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VATS
Description: Video-assisted lung segmentectomy
Study NCT01397045 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mini thoracotomy
Description: Mini muscle sparing thoracotomy for lung segmentectomy
Study NCT01117025 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Circumferential PV isolation
Description: The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
Study NCT01117025 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Circumferential PVI+renal denervation
Description: The procedure of AF ablation is the same like in the circumferential PV isolation.~After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.
Study NCT02391974 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PERIOSYAL FILL
Description: Injection 2 weeks after standard periodontal treatment procedure on all teeth that need to be treated.~Touch-up treatment provided at 3 and 6 weeks.
Study NCT00457756 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BiosLife Complete
Study NCT00106340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vildagliptin matching placebo
Study NCT00106340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride matching placebo
Study NCT00634881 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab i.v.
Description: Alemtuzumab will be administered once per week as a 2 h infusion~* Dose level I: 10mg once weekly (start with dose escalation : 3 mg on day 1, 10mg on day 2) Duration~* Dose level II: 20mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 20mg on day 3)~* Dose level III: 30mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 30mg on day 3)
Study NCT00634881 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab s.c.
Description: Alemtuzumab will be administered once per week subcutaneously~* Dose level I: 10mg once weekly (start with dose escalation : 3 mg on day 1, 10mg on day 2) Duration~* Dose level II: 20mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 20mg on day 3)~* Dose level III: 30mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 30mg on day 3)
Study NCT01930955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: β-lactam antibiotics
Study NCT03810014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditional ACT subsidy, Arm 1 levels
Description: The subsidy levels for participants randomly assigned to Arm 1 are: No subsidy for RDT (price to consumer=$0.40); 100% ACT subsidy (price to consumer=0).
Study NCT03810014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditional ACT subsidy, Arm 2 levels
Description: The subsidy levels for participants randomly assigned to Arm 2 are: No subsidy for RDT (price to consumer=$0.40); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age).
Study NCT03810014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditional ACT subsidy, Arm 3 levels
Description: The subsidy levels for participants randomly assigned to Arm 3 are: 50% subsidy for RDT (price to consumer=$0.20); 100% ACT subsidy (price to consumer=0).
Study NCT03810014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditional ACT subsidy, Arm 4 levels
Description: The subsidy levels for participants randomly assigned to Arm 4 are: 50% subsidy for RDT (price to consumer=$0.20); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age)
Study NCT02528513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to RASS score (-3 to 0).
Study NCT02528513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl is used with bolus dosage of 1-2ug/kg and maintenance dosage of 1-2ug/kg/h, with the dosage adjusted to critical care pain observation tool（CPOT）score(0-1).
Study NCT02528513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: After the spontaneous breathing trial safety screen is passed, midazolam is switched to propofol, which is administered at the maintenance dosage of 0.50-3.00mg/kg/h, with the dosage adjusted to RASS score (-2 to 0).
Study NCT01151020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenith® TX2® Low Profile TAA Endovascular Graft
Description: Endovascular treatment of patients with aneurysms/ulcers of the descending thoracic aorta having morphology suitable for endovascular repair
Study NCT00610259 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief behavioral therapy for insomnia (bBT-I)
Description: 4 50-minute individual sessions every week for 4 weeks
Study NCT00610259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: The psychiatrist-in-charge sees the patient once every 2 weeks for approximately 10 minutes each to monitor pharmacotherapy.
Study NCT00610259 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: The psychiatrist-in-charge sees the patient once every 2 weeks for approximately 10 minutes each to monitor pharmacotherapy.
Study NCT01925768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg
Description: 30mg of Apremilast will be orally administered twice daily for 104 weeks
Study NCT01925768 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically appearing Placebo tablets will be orally administered twice daily for up to 24 weeks
Study NCT02372695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Study NCT01962428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticagrelor
Description: Patients will receive ticagrelor 360mg loading dose or 180mg loading dose , then 90mg bid maintenance dose starting 12 hours after loading dose.
Study NCT01962428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: Patients will receive ticagrelor 360mg loading dose or 180mg loading dose , then 90mg bid maintenance dose starting 12 hours after loading dose.
Study NCT03235193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Severe Sepsis Prediction
Description: Upon receiving an InSight alert, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
Study NCT03235193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Severe Sepsis Detection
Description: Upon receiving information from the severe sepsis detector in the CHH electronic health record, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
Study NCT03235193 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Severe Sepsis Detection
Description: Upon receiving information from the severe sepsis detector in the CHH electronic health record, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
Study NCT04760483 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SoracteLite(TM) TPLA for BPH
Description: see prior section
Study NCT02819297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI400 Laxative
Description: 21 gm BLI400 powder
Study NCT02819297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BLI400 Placebo
Description: Equivalent amount of placebo powder
Study NCT02069977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Study NCT00260728 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vascular access graft implantation
Description: vascular access graft implantation
Study NCT02487758 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ridge Preservation
Description: Ridge Preservation Comparing the Clinical and Histologic Healing of Flap vs. Flapless Approach to Grafting
Study NCT02528513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: After the spontaneous breathing trial safety screen is passed, midazolam is switched to dexmedetomidine, which is administered at an infusion bolus of 0.5μg/kg over 10 min (given or not according to patients' condition) and the maintenance dosage of 0.2-0.7ug/kg/h, with the dosage adjusted to RASS score (-2 to 0).
Study NCT02528513 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure:sedation assessment
Description: The nursing staff continuously monitored the sedation depth and adjusted the dosages of sedative and analgesic drugs to maintain the sedation target level. The sedation depth were assessed and recorded every 4 h (or more frequently when indicated).
Study NCT00530634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00530634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00530634 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Study NCT00530634 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Study NCT00530634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT00530634 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00530634 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT03207854 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of peripheral blood, bone marrow, and tissue
Study NCT03207854 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03207854 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00530634 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT04023383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 cc HyaRegen NCH gel
Description: After an extensive bleeding control the patients in the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity.
Study NCT04023383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 40 cc sterile saline solution
Description: After an extensive bleeding control the patients in the control group had 40 cc sterile saline solution compatible with the body temperature.
Study NCT01364129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ophthalmic Telemedicine
Description: Participants receiving the intervention have digital images of their retina captured with a non-mydriatic camera. The images are then sent to Devers Eye Institute for review and report generation.
Study NCT00457756 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01175590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besivance
Description: Ocular administration to affected eye for 7 days
Study NCT00755963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol valerate
Description: Progynova® 21; 2mg/d
Study NCT00755963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micronized progesterone
Description: Utrogestan®; 200mg/d
Study NCT05430932 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy
Description: Laparoscopic resection of a part of the stomach to enable the patient to lose weight.
Study NCT00923156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aliskiren
Description: Aliskiren 150 mg once daily up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site
Study NCT00923156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramipril
Description: 2.5 mg , 5.0 mg or 10 mg once daily
Study NCT00923156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to aliskiren
Description: matching placebo to aliskiren in double blind phase
Study NCT00923156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to ramipril
Description: Matching placebo to ramipril capsule in double blind phase
Study NCT01954719 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cervix dilated after surgery
Description: The surgeon inserted his or her double-gloved index digit in the cervical canal to dilate it and removed the outer gloves after digital dilatation of the cervix.
Study NCT01954719 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: control group
Description: surgeon not dilated cervix after surgery
Study NCT04490850 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample
Study NCT05476471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multicomponent exercise training program
Description: One supervised 60 minutes training sessions per week were organized combining warm-up, speed-walking, resistance exercise, static and dynamic balance. Supervised walking sessions were for 10-20 minutes at a target intensity of 13-15 on the Borg scale. Thereafter, 10 resistance exercises targeting lower body, trunk and upper body muscles were performed with elastic band. In addition, participants were instructed to accumulate 150 minutes per week of moderate intensity aerobic activity in bouts of at least 10 minutes, and at least 2-3 days all major muscle groups training.
Study NCT00749645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FANG(30)
Description: Andrographolide formula Oral tablets, 30mg, three times per day, during a total of 105 continuous days.
Study NCT00749645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 30mg tabs, 3/day, 105 days continuously.
Study NCT03675100 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: colonoscopic mucosal biopsy
Description: colonoscopic mucosal biopsy was undertaken for every participant
Study NCT03675100 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: colonoscopic mucosal biopsy
Description: colonoscopic mucosal biopsy was undertaken for every participant
Study NCT03214939 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapy based on dendritic cells
Description: Intravenous injection of cells
Study NCT01146418 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa
Description: Single injection of 150 μg corifollitropin alfa administered under protocol P06029
Study NCT01146418 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: recFSH (follitropin beta)
Description: Daily recFSH 300 IU administered under protocol P06029.
Study NCT03845985 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Seeking Safety + Signs of Safety toolkit
Description: Seeking Safety is an existing, present-focused, first-stage manualized treatment for trauma and addiction. Session content engages clients in themes relevant to addiction and trauma, and to help them learn a specific skill to target symptoms of both AUD and PTSD (e.g., Coping with Triggers, Asking for Help).~Signs of Safety is a culturally and linguistically Deaf-accessible toolkit to be used alongside Seeking Safety. The toolkit includes a therapist guide and population-specific client materials (e.g., visual handouts; ASL teaching stories on digital video). It is designed for Deaf/signing clinicians, as well as non-signing clinicians working with ASL interpreters.
Study NCT02004119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4577
Study NCT02004119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04667871 — intervention group
Intervention type: PROCEDURE
Intervention: cataract surgery
Description: Eyes for cataract surgery